BioNotebook: Three potential IPOs and a venture capital deal; Dermira, Rhythm, Syndax, OncoPep
This article was originally published in Scrip
Executive Summary
Dermira revealed plans for a $75m initial public offering on 27 August, just one week after the company closed a $51m Series C venture capital funding round.
You may also be interested in...
IPO Update: New Filings Feed Investor Fervor As Biopharma Stocks Rise
IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.